Clinical Trials Finder
Independent ClinicalTrials.gov directory
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced May 21, 2026, 5:36 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 71 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Waldenstrom's Macroglobulinemia Clear all
Terminated Phase 2 Interventional Results available
View directory record Official record
Conditions
Waldenstrom Macroglobulinemia
Interventions
DT PACE + Rituxan
Drug
Lead sponsor
University of Arkansas
Other
Eligibility
18 Years and older
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2008
U.S. locations
1
States / cities
Little Rock, Arkansas
Source: ClinicalTrials.gov public record
Updated Aug 25, 2011 · Synced May 21, 2026, 5:36 PM EDT
Completed Phase 1Phase 2 Interventional
View directory record Official record
Conditions
Non-Hodgkins Lymphoma, B-cell Lymphoma, Waldenstrom's Macroglobulinemia, Marginal Zone Lymphoma, Chronic Lymphocytic Leukemia (CLL), Small Lymphocytic Lymphoma (SLL), Primary Central Nervous System Lymphoma
Interventions
Ublituximab
Drug
Lead sponsor
TG Therapeutics, Inc.
Industry
Eligibility
18 Years and older
Enrollment
39 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2015
U.S. locations
8
States / cities
Huntsville, Alabama • Jonesboro, Arkansas • Athens, Georgia + 5 more
Source: ClinicalTrials.gov public record
Updated Nov 20, 2022 · Synced May 21, 2026, 5:36 PM EDT
Terminated No phase listed Observational
View directory record Official record
Conditions
Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN), Chronic Lymphocytic Leukemia in Relapse, Small Lymphocytic Lymphoma, Relapsed, Waldenstrom's Macroglobulinemia Recurrent, Follicular B-cell Non-Hodgkin's Lymphoma, B-cell Lymphoma Refractory, Mantle Cell Lymphoma Recurrent, Hairy Cell Leukemia, Diffuse Large B Cell Lymphoma, Waldenstrom's Macroglobulinemia Refractory, Mantle Cell Lymphoma Refractory
Interventions
Prior MB-102 CAR-T cell investigational product., Prior MB-106 CAR-T cell investigational product.
Biological
Lead sponsor
Mustang Bio
Industry
Eligibility
18 Years and older
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
5
States / cities
Orange, California • Boston, Massachusetts • Rochester, New York + 2 more
Source: ClinicalTrials.gov public record
Updated Jul 21, 2024 · Synced May 21, 2026, 5:36 PM EDT
Terminated Phase 2 Interventional Results available
View directory record Official record
Conditions
Waldenstrom's Macroglobulinemia
Interventions
Simvastatin
Drug
Lead sponsor
Dana-Farber Cancer Institute
Other
Eligibility
18 Years and older
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2011
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Dec 15, 2015 · Synced May 21, 2026, 5:36 PM EDT
Completed Phase 1 Interventional
View directory record Official record
Conditions
B-cell Non-Hodgkins Lymphoma, Chronic Lymphocytic Leukemia
Interventions
XmAb13676
Biological
Lead sponsor
Xencor, Inc.
Industry
Eligibility
18 Years and older
Enrollment
154 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2024
U.S. locations
10
States / cities
La Jolla, California • Jacksonville, Florida • Atlanta, Georgia + 7 more
Source: ClinicalTrials.gov public record
Updated Nov 12, 2024 · Synced May 21, 2026, 5:36 PM EDT
Completed Phase 2 Interventional Results available
View directory record Official record
Conditions
Waldenstrom's Macroglobulinemia
Interventions
Ixazomib, Dexamethasone, Rituximab
Drug
Lead sponsor
Dana-Farber Cancer Institute
Other
Eligibility
18 Years and older
Enrollment
26 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2019
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Sep 1, 2020 · Synced May 21, 2026, 5:36 PM EDT
Withdrawn Phase 2 Interventional
View directory record Official record
Conditions
Lymphoma
Interventions
alemtuzumab
Biological
Lead sponsor
Jonsson Comprehensive Cancer Center
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2004
U.S. locations
10
States / cities
Los Angeles, California • Denver, Colorado • Chicago, Illinois + 5 more
Source: ClinicalTrials.gov public record
Updated Jan 7, 2013 · Synced May 21, 2026, 5:36 PM EDT
Terminated Phase 1 Interventional
View directory record Official record
Conditions
Lymphoma
Interventions
rituximab, yttrium Y 90 ibritumomab tiuxetan
Biological · Radiation
Lead sponsor
Jonsson Comprehensive Cancer Center
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2003
U.S. locations
2
States / cities
Los Angeles, California • Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jan 7, 2013 · Synced May 21, 2026, 5:36 PM EDT
Completed Phase 1 Interventional
View directory record Official record
Conditions
B Cell Non-Hodgkin's Lymphoma, Chronic Lymphocytic Leukemia, Waldenstrom Macroglobulinemia
Interventions
AVL-292
Drug
Lead sponsor
Celgene
Industry
Eligibility
18 Years and older
Enrollment
113 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2015
U.S. locations
13
States / cities
Huntsville, Alabama • Tucson, Arizona • La Jolla, California + 10 more
Source: ClinicalTrials.gov public record
Updated Nov 7, 2019 · Synced May 21, 2026, 5:36 PM EDT
Completed Phase 2 Interventional
View directory record Official record
Conditions
Leukemia, Lymphoma
Interventions
dolastatin 10
Drug
Lead sponsor
University of Vermont
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
1998 – 2003
U.S. locations
4
States / cities
Baltimore, Maryland • Detroit, Michigan • Columbus, Ohio + 1 more
Source: ClinicalTrials.gov public record
Updated Jun 25, 2013 · Synced May 21, 2026, 5:36 PM EDT
Completed Phase 1Phase 2 Interventional
View directory record Official record
Conditions
Leukemia, Lymphoma
Interventions
filgrastim, autologous bone marrow transplantation, peripheral blood stem cell transplantation, indium In 111 monoclonal antibody MN-14, yttrium Y 90 epratuzumab
Biological · Procedure · Radiation
Lead sponsor
Garden State Cancer Center at the Center for Molecular Medicine and Immunology
Other
Eligibility
18 Years to 80 Years
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 1998
U.S. locations
4
States / cities
Belleville, New Jersey • Livingston, New Jersey • Paterson, New Jersey + 1 more
Source: ClinicalTrials.gov public record
Updated Jun 21, 2011 · Synced May 21, 2026, 5:36 PM EDT
Completed Phase 1 Interventional
View directory record Official record
Conditions
Lymphoma
Interventions
2CdA, Cyclophosphamide, Rituximab
Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
Not listed
Enrollment
14 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1999 – 2022
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Mar 6, 2022 · Synced May 21, 2026, 5:36 PM EDT
Recruiting Phase 2 Interventional
View directory record Official record
Conditions
Lymphoplasmacytic Lymphoma, Waldenstrom Macroglobulinemia
Interventions
Biospecimen Collection, Bone Marrow Aspiration, Bone Marrow Biopsy, Computed Tomography, Ibrutinib, Positron Emission Tomography, Rituximab, Venetoclax, Zanubrutinib
Procedure · Drug · Biological
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
92 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2028
U.S. locations
126
States / cities
Tucson, Arizona • Coral Gables, Florida • Coral Springs, Florida + 92 more
Source: ClinicalTrials.gov public record
Updated May 19, 2026 · Synced May 21, 2026, 5:36 PM EDT
Completed Phase 2 Interventional Results available
View directory record Official record
Conditions
Waldenstrom's Macroglobulinemia
Interventions
Perifosine
Drug
Lead sponsor
Dana-Farber Cancer Institute
Other
Eligibility
18 Years and older
Enrollment
37 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2012
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Dec 25, 2017 · Synced May 21, 2026, 5:36 PM EDT
Terminated Phase 2 Interventional
View directory record Official record
Conditions
Waldenstrom Macroglobulinemia
Interventions
Epratuzumab (hLL2- anti-CD22 humanized antibody)
Drug
Lead sponsor
Gilead Sciences
Industry
Eligibility
18 Years and older
Enrollment
31 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2006
U.S. locations
2
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Aug 18, 2021 · Synced May 21, 2026, 5:36 PM EDT
Terminated Phase 2 Interventional
View directory record Official record
Conditions
Lymphoma
Interventions
bortezomib, rituximab, antibody therapy, biological therapy, enzyme inhibitor therapy, monoclonal antibody therapy
Drug · Procedure
Lead sponsor
University of Virginia
Other
Eligibility
18 Years and older
Enrollment
46 participants
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
1
States / cities
Charlottesville, Virginia
Source: ClinicalTrials.gov public record
Updated Jan 27, 2008 · Synced May 21, 2026, 5:36 PM EDT
Completed Phase 1 Interventional
View directory record Official record
Conditions
Acute Leukemia, Chronic Leukemia, Multiple Myeloma, Hodgkin's Lymphoma, Non-Hodgkin's Lymphoma, Waldenstrom's Macroglobulinemia
Interventions
AVN-944 capsules for oral administration
Drug
Lead sponsor
Vertex Pharmaceuticals Incorporated
Industry
Eligibility
18 Years and older
Enrollment
72 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2006
U.S. locations
5
States / cities
Tucson, Arizona • Stanford, California • Washington D.C., District of Columbia + 2 more
Source: ClinicalTrials.gov public record
Updated Aug 3, 2011 · Synced May 21, 2026, 5:36 PM EDT
Terminated Phase 2 Interventional Results available
View directory record Official record
Conditions
Waldenstrom's Macroglobulinemia
Interventions
CC-5103 (lenalidomide), Rituximab
Drug
Lead sponsor
Dana-Farber Cancer Institute
Other
Eligibility
18 Years to 80 Years
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2008
U.S. locations
2
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Apr 20, 2016 · Synced May 21, 2026, 5:36 PM EDT
Terminated Phase 2 Interventional Results available
View directory record Official record
Conditions
Lymphoma
Interventions
rituximab, cyclophosphamide, Doxorubicin, Prednisone, Vincristine
Biological · Drug
Lead sponsor
Eastern Cooperative Oncology Group
Network
Eligibility
18 Years and older
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2012
U.S. locations
153
States / cities
Little Rock, Arkansas • Lewes, Delaware • Newark, Delaware + 96 more
Source: ClinicalTrials.gov public record
Updated Jun 28, 2023 · Synced May 21, 2026, 5:36 PM EDT
Completed Phase 1Phase 2 Interventional Results available
View directory record Official record
Conditions
Relapsed or Refractory Lymphoproliferative Malignancies, Hodgkin's Lymphoma, Peripheral T-cell Lymphoma, B-cell Lymphoma, Waldenstrom's Macroglobulinemia
Interventions
Pralatrexate Injection, Gemcitabine Hydrochloride, Vitamin B12, Folic Acid
Drug · Dietary Supplement
Lead sponsor
Acrotech Biopharma Inc.
Industry
Eligibility
18 Years and older
Enrollment
119 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2011
U.S. locations
15
States / cities
Los Angeles, California • Stanford, California • Denver, Colorado + 11 more
Source: ClinicalTrials.gov public record
Updated Jan 6, 2020 · Synced May 21, 2026, 5:36 PM EDT
Terminated Phase 1Phase 2 Interventional Results available
View directory record Official record
Conditions
Waldenstrom's Macroglobulinemia
Interventions
Everolimus, Rituximab, Bortezomib
Drug
Lead sponsor
Dana-Farber Cancer Institute
Other
Eligibility
18 Years and older
Enrollment
46 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2014
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Apr 22, 2021 · Synced May 21, 2026, 5:36 PM EDT
Recruiting Not applicable Interventional
View directory record Official record
Conditions
Atrial Fibrillation, Supraventricular Arrhythmia, Ventricular Arrhythmias and Cardiac Arrest, Chronic Lymphocytic Leukemia, Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
Interventions
Medtronic LINQ-2 Insertable Cardiac Monitor (ILR)
Device
Lead sponsor
Northwell Health
Other
Eligibility
18 Years and older
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2030
U.S. locations
1
States / cities
New Hyde Park, New York
Source: ClinicalTrials.gov public record
Updated Sep 17, 2025 · Synced May 21, 2026, 5:36 PM EDT
Completed Phase 1 Interventional
View directory record Official record
Conditions
Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, Chronic Myelogenous Leukemia, Chronic Lymphocytic Leukemia, Multiple Myeloma, Waldenstrom's Macroglobulinemia, Myelodysplastic Syndrome, Philadelphia Chromosome-negative CML, Myeloid Metaplasia, Myelofibrosis, Advanced Polycythemia, Non-Hodgkins Lymphoma
Interventions
TAK-901
Drug
Lead sponsor
Millennium Pharmaceuticals, Inc.
Industry
Eligibility
18 Years and older
Enrollment
31 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2013
U.S. locations
1
States / cities
Ann Arbor, Michigan
Source: ClinicalTrials.gov public record
Updated Jul 1, 2013 · Synced May 21, 2026, 5:36 PM EDT
Completed Phase 2 Interventional Results available
View directory record Official record
Conditions
Waldenstrom's Macroglobulinemia, Lymphoplasmacytic Lymphoma
Interventions
Thalidomide, Rituximab
Drug
Lead sponsor
Steven P. Treon, MD, PhD
Other
Eligibility
18 Years to 80 Years
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2008
U.S. locations
2
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jun 1, 2014 · Synced May 21, 2026, 5:36 PM EDT